MAY 29, 2020 10:22 AM PDT

Advances in Our Understanding of Huntington's Disease

WRITTEN BY: Carmen Leitch

Huntington’s disease (HD) is a fatal neurodegenerative disease caused by an expanded sequence in the huntingtin gene. The disease was identified in 1872 and in 1983, Huntingtin was the first human disease-linked gene that was mapped to a chromosome. A genetic test can tell people whether they will get the disease; any child of an HD patient has a 50 percent chance of inheriting it.

Scientists have known for years that the levels of an immune molecule, interleukin-6 (IL-6), are abnormally high in HD patients, and it has been proposed that lowering the levels of this molecule could have a therapeutic effect. Reporting in Molecular Degeneration, scientists at MIT created a mouse model of Huntington's disease without IL-6. But the researchers found that these mice had even worse symptoms of the disease.

"If one looks back in the literature of the Huntington's disease field many people have postulated that reductions to IL-6 would be therapeutic in HD," said the senior study author Myriam Heiman, an associate professor at MIT's Department of Brain and Cognitive Sciences.

The scientists assessed gene expression in the regions of the brain that are significantly impacted by HD. In the mice that lacked IL-6, there was a reduction in genes that are involved in synapses. "Perhaps this worsening of the phenotype is due to perturbation of those synaptic signaling pathways," said Heiman.

In another study published in The Lancet Neurology, scientists at University College London (UCL) have identified changes in the brain that happen 24 years before the onset of HD. While there are no cures for HD, it may be possible to treat the disease if the treatment can begin before any brain damage occurs.

"Ultimately, our goal is to deliver the right drug at the right time to effectively treat this disease - ideally we would like to delay or prevent neurodegeneration while function is still intact, giving gene carriers many more years of life without impairment," said the lead author of the Lancet Neurology study, Professor Sarah Tabrizi of the UCL Huntington's Disease Centre. "As the field makes great strides with the drug development, these findings provide vital new insights informing the best time to initiate treatments in the future, and represent a significant advance in our understanding of early Huntington's."

Tabrizi and an international team of collaborators carefully assessed data from carriers of the Huntingtin mutation at a younger age than previous studies. There were 64 carriers and 67 healthy controls, and the researchers looked at brain scans, behavioral tests, and levels of proteins in spinal fluid. On average, the data was from 24 years before the onset of disease, and there weren't any detectable differences in cognition, movement, or brain structure.

However, in 47 percent of mutation carriers, there was a slight increase in the level of a protein called neurofilament light (NfL) in the spinal fluid. This protein can be a sign of nerve damage. When trajectories were modeled, the Nfl levels correlated with the predicted time of disease onset.

"We have found what could be the earliest Huntington's-related changes, in a measure which could be used to monitor and gauge [the] effectiveness of future treatments in gene carriers without symptoms," said the co-first Lancet Neurology study author, Dr. Paul Zeun of the Huntington's Disease Research Centre at UCL.

The co-first Lancet Neurology study author, Dr. Rachael Scahill of the UCL Huntington's Disease Research Centre added: "Other studies have found that subtle cognitive, motor and neuropsychiatric impairments can appear 10-15 years before disease onset. We suspect that initiating treatment even earlier, just before any changes begin in the brain, could be ideal, but there may be a complex trade-off between the benefits of slowing the disease at that point and any negative effects of long-term treatment."

Tabrizi is also part of a phase 3 clinical trial that is testing the efficacy of an HD treatment that lowers the levels of the abnormal huntingtin protein.

Sources: AAAS/Eurekalert!, Picower Institute at MIT, University College London, Molecular Neurodegeneration, The Lancet Neurology

 

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
AUG 27, 2020
Genetics & Genomics
Understanding How Animals Make Seasonal Adaptations
AUG 27, 2020
Understanding How Animals Make Seasonal Adaptations
Some animals don't need a new wardrobe to change with the seasons, and scientists have now learned more about how they d ...
SEP 02, 2020
Microbiology
A Common Bacterium Can Evolve in the Stomach
SEP 02, 2020
A Common Bacterium Can Evolve in the Stomach
Helicobacter pylori can be found in as much as fifty percent of the world's population.
SEP 07, 2020
Genetics & Genomics
Lactose Tolerance Quickly Moved Through Europe
SEP 07, 2020
Lactose Tolerance Quickly Moved Through Europe
Researchers have found evidence that humans in Europe gained the ability to metabolize the lactose, the sugar in milk, a ...
SEP 10, 2020
Genetics & Genomics
Learning More About Racial Disparities in COVID-19
SEP 10, 2020
Learning More About Racial Disparities in COVID-19
While institutional racism in the healthcare system plays a major part, there seem to also be biological reasons why the ...
OCT 14, 2020
Genetics & Genomics
Robots Are Moving Developmental Biology Forward
OCT 14, 2020
Robots Are Moving Developmental Biology Forward
Researchers have created a robot that can analyze the effects of mutations that occur in portions of the genome that hel ...
OCT 20, 2020
Genetics & Genomics
The Gene Behind the Glow of the Sea Pickle is ID'ed
OCT 20, 2020
The Gene Behind the Glow of the Sea Pickle is ID'ed
In this photo by OceanX, researchers off the coast of Brazil collected Pyrosoma atlanticum specimens with a special robo ...
Loading Comments...